Lanean...
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e., exon 19 deletions or L858R). However, acquired resistan...
Gorde:
| Argitaratua izan da: | Expert Rev Anticancer Ther |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4940973/ https://ncbi.nlm.nih.gov/pubmed/26943236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2016.1162103 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|